More than just accuracy: A pathway-level framework for implementing blood and digital biomarkers for Alzheimer's disease care.

Blood biomarkers and digital measures together can improve Alzheimer’s disease care beyond diagnostic accuracy alone.

• Why it matters: Current diagnostic tools are limited in guiding patient-centered outcomes and pathway-level decisions, which are essential for effective clinical implementation and treatment planning.
• What they did: The authors review how combined blood and digital biomarker workflows can be evaluated considering context, downstream decisions, ethics, governance, and monitoring, beyond just accuracy.
• The result: This framework aims to facilitate the translation of biomarker innovations into meaningful benefits for patients and health systems by addressing comprehensive pathway-level outcomes.